Myeloid-derived suppressor cells in malignant melanoma
Standard
Myeloid-derived suppressor cells in malignant melanoma. / Umansky, Viktor; Sevko, Alexandra; Gebhardt, Christoffer; Utikal, Jochen.
In: J DTSCH DERMATOL GES, Vol. 12, No. 11, 11.2014, p. 1021-7.Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Myeloid-derived suppressor cells in malignant melanoma
AU - Umansky, Viktor
AU - Sevko, Alexandra
AU - Gebhardt, Christoffer
AU - Utikal, Jochen
N1 - © 2014 Deutsche Dermatologische Gesellschaft (DDG). Published by John Wiley & Sons Ltd.
PY - 2014/11
Y1 - 2014/11
N2 - Melanoma is known for its rapid progression, metastasis to distant organs and therapeutic resistance. Despite high melanoma immunogenicity, the results of immunotherapeutic clinical studies are mostly unsatisfactory. One explanation is the development of strong immunosuppression mediated by highly immunosuppressive regulatory leukocytes, in particular, myeloid-derived suppressor cells (MDSCs). These cells were found to be enriched and activated in the melanoma microenvironment, inducing a profound impairment of anti-tumor immune responses and leading to the tumor progression. Therefore, understanding the mechanisms of MDSC generation, migration to the tumor site and activation as well as their targeting is important for the development of novel strategies for effective melanoma immunotherapy. We suggest that such therapeutic approaches should involve the inhibition of MDSC-mediated immunosuppressive melanoma microenvironment combined with other immunologic treatments.
AB - Melanoma is known for its rapid progression, metastasis to distant organs and therapeutic resistance. Despite high melanoma immunogenicity, the results of immunotherapeutic clinical studies are mostly unsatisfactory. One explanation is the development of strong immunosuppression mediated by highly immunosuppressive regulatory leukocytes, in particular, myeloid-derived suppressor cells (MDSCs). These cells were found to be enriched and activated in the melanoma microenvironment, inducing a profound impairment of anti-tumor immune responses and leading to the tumor progression. Therefore, understanding the mechanisms of MDSC generation, migration to the tumor site and activation as well as their targeting is important for the development of novel strategies for effective melanoma immunotherapy. We suggest that such therapeutic approaches should involve the inhibition of MDSC-mediated immunosuppressive melanoma microenvironment combined with other immunologic treatments.
KW - Animals
KW - Cytokines
KW - Humans
KW - Melanoma
KW - Models, Immunological
KW - Myeloid Cells
KW - Skin Neoplasms
KW - Tumor Microenvironment
KW - Journal Article
KW - Review
U2 - 10.1111/ddg.12411
DO - 10.1111/ddg.12411
M3 - SCORING: Review article
C2 - 25263083
VL - 12
SP - 1021
EP - 1027
JO - J DTSCH DERMATOL GES
JF - J DTSCH DERMATOL GES
SN - 1610-0379
IS - 11
ER -